Senseonics Vs. Novo Nordisk: Which Diabetes Stock Is A Better Buy?

Senseonics Holdings, Inc. (SENS - Get Rating) and Novo Nordisk A/S (NVO - Get Rating) are two established players in the medical industry. SENS is a medical technology company focused on the design, development and commercialization of glucose monitoring systems. NVO designs and manufactures pharmaceutical products. Based in Denmark, NVO operates through two segments: Diabetes and Obesity care, and Biopharm. 

Medic, Hospital, Laboratory, Medical, Health, Doctor

Image Source: Pixabay

Diabetes is rising at an alarming rate in the West, accelerated by the remote lifestyles and work-from-home routines. As a result, pharmaceutical companies have been experimenting with innovative drugs to cure and manage the ailment. Many companies have reported promising results from their clinical trials, indicating that a diabetes treatment drug might soon be available in the market. 

The size of the global diabetes drug market is projected to hit $78.30 billion by 2026, growing at a 6.1% CAGR.

While SENS has gained 312.5% over the past year, NVO has returned 25.5%. In terms of their past six months’ performance, SENS is a clear winner with 461.7% returns versus NVO’s 16.7% gains. But which of these two stocks is a better pick now? Let’s find out.

Latest Movements

On February 24, NVO and the University of Toronto announced a DKK 200 million ($32.80 million) investment to establish the Novo Nordisk Network for Healthy Populations. The network is expected to focus on new ways to support healthier urban populations by leveraging the university’s leading expertise in public health research and education programs to push forward the global fight against diabetes and other serious chronic diseases.

On February 1, SENS announced that Ascensia Diabetes Care had begun sales and marketing activities for the Eversense XL CGM system in key European markets, as part of their strategic partnership agreement announced in August 2020.

Recent Financial Results

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.